What are Live attenuated chimeric vaccine drugs?

Live attenuated chimeric vaccine drugs are pharmacologic agents that share a common mechanism (typically targeting Japanese encephalitis virus and dengue virus (serotypes 1-4) structural antigens). 0 are currently marketed, with 3 more in clinical development.

Live attenuated chimeric vaccine

0 marketed 3 in Phase 3

This page covers all Live attenuated chimeric vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Japanese encephalitis virus and dengue virus (serotypes 1-4) structural antigens.

Targets

Japanese encephalitis virus and dengue virus (serotypes 1-4) structural antigens

Phase 3 pipeline (3)

ChimeriVax™-JE · Sanofi · Infectious Disease / Immunology
ChimeriVax-JE is a live attenuated chimeric vaccine that combines the yellow fever vaccine backbone with Japanese encephalitis virus envelope genes to induce protective immunity against Japanese encephalitis.
ChimeriVax-JE, Japanese Encephalitis vaccine · Sanofi · Infectious Disease / Immunology
ChimeriVax-JE is a live attenuated chimeric vaccine that uses a yellow fever virus backbone expressing Japanese encephalitis virus envelope proteins to induce protective immunity against Japanese encephalitis.
JE-CV Vaccine · Sanofi Pasteur, a Sanofi Company · Infectious Disease / Immunology
JE-CV is a chimeric vaccine that combines the live attenuated Japanese encephalitis virus backbone with dengue virus structural proteins to provide protection against both Japanese encephalitis and dengue viruses.